Known targets — ChEMBL curated mechanism
FLT1FLT3FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Su-014813. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 13/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 12/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 4/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 8/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 7/20 | 1.00 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 1.00 |
| ▸ | RIOK2 | Q9BVS4 | 3/20 | 1.00 |
| ▸ | TLK1 | Q9UKI8 | 3/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 3/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 3/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 3/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 3/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 3/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Su-014813 SCHEMBL4500940 | 1.00 | KDR (1.00) | KDRPDGFRBFGFR1PRKAA1PRKAA2 | |
| Su-014813 SCHEMBL902507 | 1.00 | KDR (1.00) | KDRPDGFRBFGFR1PRKAA1PRKAA2 | |
| Su-014813 SCHEMBL4500929 | 1.00 | KDR (1.00) | KDRPDGFRBFGFR1PRKAA1PRKAA2 | |
| Su-014813 SCHEMBL2334610 | 1.00 | KDR (1.00) | KDRPDGFRBFGFR1PRKAA1PRKAA2 | |
| Su-014813 SCHEMBL1249521 | 1.00 | KDR (1.00) | KDRPDGFRBFGFR1PRKAA1PRKAA2 | |
| Su-014813 SCHEMBL30030129 | 0.96 | KDR (0.93) | KDRPDGFRBFGFR1PRKAA1PRKAA2 | |
| Su-014813 SCHEMBL3367375 | 0.96 | KDR (0.93) | KDRPDGFRBFGFR1PRKAA1PRKAA2 | |
| Su-014813 SCHEMBL3367367 | 0.96 | KDR (0.93) | KDRPDGFRBFGFR1PRKAA1PRKAA2 | |
| SCHEMBL13711974 | 0.92 | PDGFRB (0.86) | KDRPDGFRBFGFR1PRKAA1PRKAA2 | |
| SCHEMBL5527704 | 0.91 | KDR (0.83) | KDRPDGFRBFGFR1PRKAA1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021007512-A1 | PLATINUM-BASED CHEMOTHERAPY, MAST BINDING AGENTS, GLUCOCORTICOID RECEPTOR (GR) BINDING AGENTS, AND/OR HSP90 BINDING AGENTS FOR USES IN TREATING CANCER | EMORY UNIVERSITY (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2019144012-A1 | MAST1 AND USES FOR DIAGNOSING AND TREATING CANCER | EMORY UNIVERSITY (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-7256189-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256189-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7247627-B2 | non-hygroscopic, crystalline anhydrous maleate salt of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | PHARMACIA & UPJOHN COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-7179910-B2 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179910-B2 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20040229930-A1 | Formulations comprising a basic indolinone compound | PHARMACIA ITALIA S.P.A. | 2004-11-18 | — | — | US | disclosed |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | KDR 4180/4885PDGFRB 1236/4885KIT 1136/4885 |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | MKI67, CCNA1, CCNI | KDR 3687/4885PDGFRB 3475/4885KIT 303/4885 |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | KDR 281/4885PDGFRB 694/4885KIT 615/4885 |
| US-20040229930-A1 | Formulations comprising a basic indolinone compound | PDPK1, HASPIN, IP6K1 | KDR 1878/4885PDGFRB 2045/4885KIT 528/4885 |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | FLT3, FLI1, MCL1 | KDR 71/4885PDGFRB 123/4885KIT 9/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | KDR 4180/4885PDGFRB 1236/4885KIT 1136/4885 |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | PDPK1, MAP4K2, MAP4K3 | KDR 1334/4885PDGFRB 1062/4885KIT 1899/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | KDR 283/4885PDGFRB 679/4885KIT 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.